Lithovius, Raija
Mutter, Stefan
Parente, Erika B.
Mäkinen, Ville-Petteri
Valo, Erkka
Harjutsalo, Valma
Groop, Per-Henrik
Funding for this research was provided by:
Diabetestutkimussäätiö
Article History
Received: 23 May 2023
Accepted: 11 October 2023
First Online: 19 October 2023
Competing interests
: P.-H.G. has received lecture honoraria from Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, EloWater, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, Peer Voice, Sanofi and Sciarc. P-H.G. is an advisory board member for AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. P-H.G. has received investigator-initiated grants from Eli Lilly and Roche. E.B.P. reports receiving lecture honorariums from Eli Lilly, Abbott, Astra Zeneca, Sanofi, and Boehringer Ingelheim and is an advisory board member of Sanofi. No other potential conflicts of interest relevant to this article were reported. The funding sources were not involved in the design or conduct of the study. All other authors declare that there is no duality of interest associated with this manuscript.